But GAO insists cancer care won't suffer next year
Oncologists should be able to afford the new, reduced payments for medications that take effect in January, claims the Government Accountability Office in a new report ("Medicare Chemotherapy Drugs: New Drug And Administration Fees Are Closer To Providers' Costs," GAO-05-142R). The GAO studied 16 drugs commonly billed by oncologists and found that Medicare payments would be 22 percent above oncologists' costs in 2004 and 6 percent above their costs in 2005.
The American Society for Clinical Oncology responded that a survey of its members found that payments would be only 4 percent above members' costs in 2005. And ASCO criticized the GAO study for failing to account for the severe variations in the acquisition cost for drugs among different providers.
The GAO insists that even though Medicare practice expense payments will drop overall in 2005, they'll cover "nearly as much or more of oncologists' costs than will payments for all services to all specialties." But ASCO responds that other specialties reap more of their revenues from payments for the physician work RVUs than oncologists, and thus other specialties can more easily stand to lose on practice expense payments.
CMS Administrator Mark McClellan is a top contender to take the helm at HHS. But losing its second administrator in less than a year could be a heavy drain on CMS, which has yet to complete implementation of the Medicare Modernization Act. Thompson will remain in office until Feb. 4, or until a new secretary is confirmed.
Prosecutors say 20 clinics allegedly claimed services directly performed by faculty members without enough evidence to prove that the doctors had been personally involved in performing the services. They also allegedly billed for a higher level of service than they performed.